SecBot SecBot

NNNN

Anbio Biotechnology
Nasdaq· In Vitro & In Vivo Diagnostic Substances· Inc. E9· CIK 0001982708 Biotech & Drug Discovery
$3.81 +0.10 (+2.70%)
Oct 23 4:00 PM ET · prev $3.71
Market cap
$533.8M
Small cap
1 year
−84.1%
from $23.92 · Oct 27
30 days
−37.4%
from $6.09
52-week range
$3.13–41.11
−91% from high · low Oct 16
Avg volume 20D
55.5K
Oct 20 spike 237.8K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read BEARISH 3 reports · latest
Balance 1 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 3/3
Strongest BEARISH Anbio Biotechnology filed proxy materials for a May 15, 2026 EGM seeking approval for a massive authorized…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    36% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT828$11.4K

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 17, 2026 Trading halt
Halt Resumed: NNNN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-17T13:39:47.000Z | Resumed 2026-08-17T13:44:47.000Z
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
828 shares ($11.4K)
May 19, 2026 SEC
Anbio Biotechnology held an EGM on May 15, 2026, approving a share capital reduction, a massive increase in authorized…
6-K — Impact 4/10
Apr 27, 2026 SEC
Anbio Biotechnology filed proxy materials for a May 15, 2026 EGM seeking approval for a massive authorized share…
6-K — Impact 7/10
Apr 7, 2026 SEC
Anbio Biotechnology's 20-F filing reveals strong financial growth with net income surging 170% YoY to $6.4M in 2025…
20-F — Impact 6/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Aug 17, 2026Volatility PauseResumed
Jul 30, 2026Volatility PauseResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 17, 2026
Trading halt
Halt Resumed: NNNN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-08-17T13:39:47.000Z | Resumed 2026-08-17T13:44:47.000Z
Aug 17, 2026
Trading halt
Trading Halt: NNNN — LUDP (Volatility Trading Pause)
Anbio Biotechnology Cl A Ord S | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Jul 30, 2026
Trading halt
Halt Resumed: NNNN — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-30T17:41:26.000Z | Resumed 2026-07-30T17:46:26.000Z
Jul 30, 2026
Trading halt
Trading Halt: NNNN — LUDP (Volatility Trading Pause)
Anbio Biotechnology Cl A Ord S | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Mar 17, 2026
Press release
Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum
FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ: NNNN) ("Anbio" or the "Company"), a global diagnostic…

SecBot reports

3 filings · 0 bullish · 1 bearish · 1 mixed · 1 neutral
All NNNN filing & press-release reports (3)